Aug 2026· The Egyptian Journal of Neurology Psychiatry and Neurosurgery· Vol 62· 0 citations· 93 references
TL;DR
Overall, symptomatic therapies continue to represent the foundation of AD management, whereas anti-amyloid monoclonal antibodies mark an important, although incremental, transition toward disease modification in carefully selected patients.
Abstract
Alzheimer’s disease (AD) is the leading cause of dementia worldwide and poses an increasing challenge for ageing populations. For decades, pharmacologic management has relied on cholinesterase inhibitors and memantine, which provide modest symptomatic benefit without altering the underlying neurodegenerative process. Recent advances in anti-amyloid monoclonal antibodies and investigational therapies targeting tau pathology, neuroinflammation, and metabolic dysfunction have renewed interest in disease-modifying therapies. This PRISMA 2020-guided narrative review critically evaluates current and emerging pharmacotherapies for AD, with emphasis on clinical efficacy, safety, and relevance to geriatric practice. A structured search of PubMed/MEDLINE, Embase, Scopus, Web of Science, CENTRAL, and ClinicalTrials.gov identified 71,663 records published between January 2000 and January 2026. After screening and eligibility assessment, 18 randomized and phase II/III clinical trials were included in the qualitative synthesis. Owing to substantial heterogeneity in study design, patient populations, and outcome measures, findings were synthesized narratively rather than quantitatively. Cholinesterase inhibitors and memantine were associated with small-to-moderate improvements or stabilization in cognition and global function, although limited durability and tolerability may restrict long-term use. Anti-amyloid monoclonal antibodies, particularly lecanemab and donanemab, demonstrated statistically significant slowing of cognitive decline in early AD; however, the absolute clinical benefits remained modest and were accompanied by amyloid-related imaging abnormalities, necessitating careful monitoring with magnetic resonance imaging. Emerging therapies targeting tau pathology, neuroinflammatory pathways, and metabolic dysfunction remain investigational. Overall, symptomatic therapies continue to represent the foundation of AD management, whereas anti-amyloid monoclonal antibodies mark an important, although incremental, transition toward disease modification in carefully selected patients.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide accounting for an estimated 60% to 80% of cases. Biomarkers play an integral role in AD randomized clinical trials (RCTs), providing objective measures of disease pathology, progression, and therapeutic effi...
Xiao-Lan Zhang, Michael F. Murphy, Henry J. Riordan et al.· Bioanalysis· 0 citations
Alzheimer’s disease (AD) is one of the leading neurodegenerative disorders affecting over 55 million
individuals worldwide, with a limited selection of disease-modifying therapies. The amyloid cascade
hypothesis proposes that amyloid-beta (Aβ) peptide accumulation initiates a cascade of synaptic
dysfunction, neuroinfla...
R. Menon· American Journal of Student...· 0 citations
INTRODUCTION
Dementia with Lewy bodies (DLB) is characterized by progressive cognitive, neuropsychiatric, motor, autonomic, and sleep impairment. Pharmacological interventions developed with disease-modifying intent have entered clinical testing, but their biological rationale and adequacy of evaluation remain uncertai...
Deirdre M. O'Shea, Shanell Disla, Alyssa Gosling et al.· Expert Review of Clinical Ph...· 0 citations
Recommendations are made regarding necessary literature reviews, including qualitative data and related conceptual models, disease models including pathophysiology and neuropsychological profile, and clinical outcome assessment (COA) reviews, including content validity, psychometrics, and fitness-for-purpose.
Chris J. Edgar, Kathleen L. Poston, Cheryl D. Coon et al.· Journal of Parkinson's Disea...· 0 citations
Despite remaining challenges, including safety concerns and the risk of amyloid-related imaging abnormalities, anti-amyloid therapies represent a major advancement in the treatment of Alzheimer's disease and mark a transition toward disease-modifying strategies.
Kacper Jaskulski, Katarzyna Kowalenko, J. Szadkowski et al.· International Journal of Inn...· 0 citations
Purpose To provide an updated, clinically oriented overview of therapeutic strategies for Parkinson’s disease-related psychosis (PDP), integrating current evidence on risk factors and available pharmacological and non-pharmacological treatments. Patients and Methods This is a narrative, non-systematic review summarizin...
N. Rocha, Karina Lucia Moreira Sassi, Erin Furr Stimming et al.· Clinical Pharmacology : Adva...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.